A van Elsas
Overview
Explore the profile of A van Elsas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Elsas A, Aarnoudse C, van der Minne C, Van der Spek C, Brouwenstijn N, Osanto S, et al.
J Immunother
. 1997 Oct;
20(5):343-53.
PMID: 9336741
We have transfected human melanoma cell line 518A2 with the cDNA encoding interleukin-2 (IL-2) or granulocyte-macrophage colony-stimulating factor (GM-CSF), and compared cytokine-producing clones for their ability to induce melanoma-specific cytotoxic...
12.
van Elsas A, Scheibenbogen C, van der Minne C, Zerp S, Keilholz U, Schrier P
Melanoma Res
. 1997 Aug;
7 Suppl 2:S107-13.
PMID: 9578425
Human cutaneous melanoma is heterogeneous with respect to the genetic aberrations involved and the genes altered are potential targets for the immune system. The incidence of cutaneous melanoma is known...
13.
Jansen B, Eichler H, Wolff K, van Elsas A, Schrier P, Pehamberger H
Cancer Res
. 1997 Feb;
57(3):362-5.
PMID: 9012455
Activation of the N-ras gene by point mutations occurs in about 15 % of all human melanomas. Using recently established melanoma severe combined immunodeficiency-human mouse xenotransplantation models, here we further...
14.
Jansen B, Inoue S, Wadl H, Eichler H, Wolff K, van Elsas A, et al.
Int J Cancer
. 1996 Sep;
67(6):821-5.
PMID: 8824554
Fifteen percent of all human melanomas carry mutations in ras genes, the majority of which are located in codon 61 of the N-ras gene. However, the biological significance of these...
15.
van Elsas A, Zerp S, van der Flier S, Kruse K, Aarnoudse C, Hayward N, et al.
Am J Pathol
. 1996 Sep;
149(3):883-93.
PMID: 8780392
Intermittent or recreational exposure to sunlight is thought to contribute to development of human cutaneous melanoma. We investigated the incidence of ras oncogene mutation in human cutaneous melanoma in connection...
16.
van Elsas A, van der Burg S, van der Minne C, Borghi M, Mourer J, Melief C, et al.
Eur J Immunol
. 1996 Aug;
26(8):1683-9.
PMID: 8765006
The melanoma antigen Melan-A/MART-1 was screened for the presence of potential HLA-A*0201-binding cytotoxic T lymphocytes (CTL) epitopes. The immunodominant nonamer epitope AAGIGILTV demonstrated weak binding to T2 but a significant...
17.
van Elsas A, Nijman H, van der Minne C, Mourer J, Kast W, Melief C, et al.
Int J Cancer
. 1995 May;
61(3):389-96.
PMID: 7729952
The ras oncogene is frequently found to be activated in human cancer through point mutations at codons 12, 13 or 61. We explored whether these altered p21ras protein sequences contain...
18.
Visseren M, van Elsas A, van der Voort E, Ressing M, Kast W, Schrier P, et al.
J Immunol
. 1995 Apr;
154(8):3991-8.
PMID: 7706738
CTL that lyse melanoma cells were previously isolated from several melanoma patients. Such CTL recognize autologous proteins, indicating the occurrence of autoreactive T cells in melanoma patients. We have now...
19.
van Elsas A, Zerp S, van der Flier S, Vacca A, Ruiter D, Schrier P
Recent Results Cancer Res
. 1995 Jan;
139:57-67.
PMID: 7597312
Determination of the activation state of oncogenes as well as tumor suppressor genes is a main subject of interest in the analysis of the mechanism of tumor initiation. In human...
20.
van Elsas A, van Deursen E, Wielders R, Schrier P
J Invest Dermatol
. 1994 Nov;
103(5 Suppl):117S-121S.
PMID: 7963672
An important phenomenon in tumor immunology that has come under recent attention is the impact of oncogene activation in tumor cells on the sensitivity to lysis by immune effector cells....